Niagara Falls, ON

Join us in spectacluar Niagara Falls, ON for 3 days of cannabis cultivation, psychedelics and extraction.

September 12-14, 2022

Grow Up Awards Gala

Annual Grow Up Industry Awards. Come celebrate the innovation and sucess in the cannabis growing industry.

September 12, 2022, Niagara Falls

High-strength cannabis more associated with addiction than low-potency weed: Study

Jul 26, 2022 | Media Partners, The GrowthOp

This post is presented by our media partner The Growth Op
View the original article here.

Investigators out of the U.K. considered 20 studies involving almost 120,000 people

Article content

A U.K. review of 20 studies suggests the rate of people treated for cannabis addiction has risen in line with higher THC levels found in weed internationally.

Advertisement 2

Story continues below

Article content

Published this week in The Lancet Psychiatry, investigators from the Addiction and Mental Health Group at the University of Bath wanted to see if there was an association between cannabis potency — THC concentration in weed — and mental health and addiction in users.

Their systematic review involved perusing several databases that included human observational studies on health conditions — such as depression, anxiety, psychosis or cannabis use disorder (CUD) — and comparing the effects of using products with high or low THC levels.

  1. Requirements on edibles packages include limited branded elements, prominent health warning labels, serving size, nutritional information and the amounts of cannabis compounds. /

    Young adults say cannabis edibles packaging should promote safe use, not preach deterrence: Canadian study

  2. Researchers have been investigating the connection between cannabis use and schizophrenia since the late 1960s. PHOTO BY GETTY IMAGES

    Cannabis: Increased schizophrenia risk in young people linked to both low and high use

  3. Medical cannabis products would be exempt from the limit in Washington state, although the bill listed certain conditions for medical cannabis retailers as well.

    Washington state lawmakers table bill that would effectively ban adult-use concentrates

Advertisement 3

Story continues below

Article content

Of the 20 studies that met eligibility criteria, which involved almost 120,000 people, eight focused on psychosis, eight on anxiety, seven on depression and six on CUD.

Adult-use cannabis remains illegal throughout the U.K.

The review indicated that “overall, use of higher-potency cannabis, relative to lower-potency cannabis, was associated with an increased risk of psychosis and CUD,” study authors write.

Investigators point out, however, that standardized exposure measures and longitudinal designs are needed to “strengthen the evidence” of any association of cannabis potency with CUD and psychosis.

As for depression and anxiety, the study abstract states that the “evidence varied.”

In a statement from the University of Bath, “despite anecdotal evidence of links between cannabis and anxiety and depression, the authors note the links between cannabis potency and other mental health problems are unclear.”

Advertisement 4

Story continues below

Article content

Per the university, the latest available estimates out of the U.K. show that one in five 16- to 24-year-olds used cannabis over the past year.

THC concentration in international cannabis markets is also greater than in years past, with a university study from two years ago finding that potency rose between 1970 and 2017 while CBD remained stable. “Increases in THC were greater in cannabis resin than herbal cannabis,” study authors wrote at the time.

In the new study, authors say findings “may help to explain why more people have received treatment for cannabis problems over recent years.”

Data from the European Monitoring Centre for Drugs and Drug Addiction show a 76 per cent increase in people entering treatment for cannabis addiction in the past decade, notes the university statement.

Advertisement 5

Story continues below

Article content

Study authors are encouraging changes to public health guidelines and policies to help make cannabis use safer.

Findings that people who use higher-potency cannabis could be at relatively increased risks of addiction and psychosis “are important in the context of harm reduction, which aims to minimize the negative consequences associated with drug use,” lead author Kat Petrilli argues in the statement.

A study published in JAMA Psychiatry two years ago noted that using high-potency cannabis is associated with mental health and addiction.

“Limiting the availability of high-potency cannabis may be associated with a reduction in the number of individuals who develop cannabis use disorders, the prevention of cannabis use from escalating to a regular behaviour and a reduction in the risk of mental health disorders,” the study abstract reads.

Advertisement 6

Story continues below

Article content

“While the safest level of use for cannabis is, of course, ‘no use,’” Petrilli says of the latest findings, “it is important to acknowledge that a significant number of people across the world use cannabis regularly and to ensure they can make informed decisions that could reduce any possible harms associated with it.”

States senior author Tom Freeman, “Our findings suggest that people who use cannabis could reduce their risk of harm by using lower-potency products.”

Any such efforts would be enhanced by “providing consumers with accurate information on product content and access to lower-potency products” in places where cannabis is legally sold, Freeman suggests.

But labelling of cannabis products, legal and illicit, continues to be a challenge.

Advertisement 7

Story continues below

Article content

A Canadian study from earlier this year compared illicit cannabis products to their legal counterparts. Researchers found lower than advertised levels of THC in unregulated products and pesticide levels that are several hundred times above Health Canada’s limits.

This past May, U.S. investigators suggested nutrition-like labels for cannabis would provide customers with more accurate information about what’s in weed products. Their analysis found that labels like indica, sativa and hybrid are a bust.

And just this month, a new study from Johns Hopkins University School of Medicine determined a selection of CBD products available from national retailers in the U.S. are inaccurately labelled.

Subscribe to Weekend Dispensary, a weekly newsletter from The GrowthOp.

Advertisement 1

Story continues below


Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

This post was originally published by our media partner here.


O’Cannabiz – June 1-3, 2022
International Convention Centre, Toronto ON

Grow Up – June 20-22, 2022
Victoria Convention Centre, Victoria ON

Grow Up – September 12-14, 2022
Niagara Falls Convention Centre, ON

News from Grow Up Media partners